Literature DB >> 9304411

The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow.

S Murakami1, Y Ohta, Y Asami, I Yamagishi, Y Toda, M Sato, K Tomisawa.   

Abstract

1. A novel ACAT (acyl-CoA: cholesterol acyltransferase) inhibitor, HL-004, exhibited a strong inhibitory effect on the hepatic and intestinal ACAT, but was less effective on the adrenal ACAT in vitro. 2. HL-004 selectively decreased serum VLDL cholesterol, and inhibited hepatic ACAT activity in hamsters fed normal chow. 3. These results suggest that the cholesterol-lowering effect of HL-004 can be attributed to a decrease in hepatic VLDL secretion via inhibition of ACAT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9304411     DOI: 10.1016/s0306-3623(96)00070-5

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  2 in total

Review 1.  Genetics and molecular biology: macrophage ACAT depletion - mechanisms of atherogenesis.

Authors:  David Akopian; Jheem D Medh
Journal:  Curr Opin Lipidol       Date:  2006-02       Impact factor: 4.776

2.  Lipid-lowering effects of WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolase.

Authors:  B R Krause; D R Sliskovic; M Anderson; R Homan
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.